genedrive plc

("genedrive" or the "Company")

Royal Sussex County Hospital, Brighton adopts the Genedrive® MT-RNR1 ID Kit for routine use

 Further expansion of hearing loss test into the NHS

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces the Genedrive® MT-RNR1 ID Kit is now in routine use in the Trevor Mann Baby Unit ("TMBU") at the Royal Sussex County Hospital ("RSCH"), part of University Hospitals Sussex NHS Foundation Trust. This site is the second NHS Trust in the country to be using the Genedrive test for antibiotic induced hearing loss ("AIHL").

Each year approximately 450 babies are admitted to the neonatal unit in Brighton. The simple, non-invasive test will be used routinely to guide treatment prescription within the unit from today, 4 December 2023.

Inspiration Healthcare and Genedrive have been working closely with the team at the TMBU, providing training and support, to ensure the smooth implementation of the pharmacogenetic point of care test into the neonatal admission process. Every mother and child that comes to RSCH, will now have access to the life-changing test, should it be required.

James Cheek, Chief Executive Officer of genedrive plc, said: "Both children and parents in Sussex will have their lives and patient pathways enhanced by having access to this test. It also brings peace of mind and support to clinicians in very stressful circumstances to make the right decision for the patient. On a wider scale, it's great to see how rapid Pharmacogenetics testing is transforming healthcare in time-critical settings, and improving patient safety."

For further details, please contact:

About genedrive plc (http://www.genedriveplc.com) 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge which circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes, ensuring vital care is delivered with no negative impact on the patient pathway.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.